Summary
This 8-K filing from Cencora, Inc. (then AmerisourceBergen Corporation) on September 8, 2009, provides an update regarding the company's participation in the Robert W. Baird & Company, Inc. 2009 Healthcare Conference. The key takeaway for investors is the reaffirmation of the company's fiscal year 2009 earnings guidance. Management expects diluted earnings per share from continuing operations to be at the higher end of the previously stated range of $1.59 to $1.65.
Key Highlights
- 1Cencora (AmerisourceBergen) management will present at the Robert W. Baird & Company Healthcare Conference.
- 2Chief Financial Officer Michael D. DiCandilo and EVP Steven H. Collis are scheduled to speak.
- 3The company reaffirms its fiscal year 2009 diluted earnings per share guidance.
- 4Expected diluted EPS for FY2009 is at the higher end of the $1.59 - $1.65 range.
- 5This represents an anticipated 10% to 15% increase over the prior year's split-adjusted EPS of $1.44.
Frequently Asked Questions
The main purpose of this filing is to inform investors that Cencora (AmerisourceBergen) management will be presenting at a healthcare conference and to reaffirm the company's full-year fiscal 2009 earnings guidance.
The company is reaffirming its expectation that diluted earnings per share from continuing operations for fiscal year 2009 will be at the higher end of the range of $1.59 to $1.65.
The reaffirmed guidance suggests an expected increase of 10% to 15% in diluted EPS for fiscal year 2009 compared to the split-adjusted EPS of $1.44 in fiscal year 2008.
Executive Vice President and Chief Financial Officer Michael D. DiCandilo and Executive Vice President and President AmerisourceBergen Drug Corporation Steven H. Collis will be speaking at the conference.